# US 2015/0175603 A1 · Tricyclic compounds as kat ii inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175603 A1
- Document ID: US20150175603A1
- Status: Published application
- Kind: A1
- Application number: 14/405,103
- Filed: 2013-06-03
- Published: 2015-06-25
- Earliest claimed: 2012-06-15
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Amy Beth Dounay; Jamison Bryce Tuttle; Patrick Robert Verhoest
- Web page: https://patentgrep.com/patent/US20150175603A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula (I), wherein R1, R2, X1, Y1, Z1, and Z2 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
represents a single bond or a double bond;
X1 is CR3 or N;
Y1 is CR4 or N;
Z1 is CR5 or C(═O);
Z2 is N, NH, or O;
R1 is Q1, —O-Q1, or —CH2-Q1;
R2 is H, OH, —CN, halogen, optionally substituted C1-4 alkyl, or optionally substituted C1-4 alkoxy;
each of R3 and R4 is independently H, OH, —CN, halogen, optionally substituted C1-4 alkyl, or optionally substituted C1-4 alkoxy;
R5 is H, OH, —CN, C1-3 alkyl optionally substituted with one or more halogen, or C1-3 alkoxy optionally substituted with one or more halogen; and
Q1 is optionally substituted phenyl or optionally substituted 5- to 10-membered heteroaryl.

### Claim 2

A compound of Formula Ia, Ib, or Ic:
or a pharmaceutically acceptable salt thereof, wherein:
X1 is CR3 or N;
Y1 is CR4 or N;
R1 is Q1, —O-Q1, or —CH2-Q1;
R2 is H, OH, —CN, halogen, optionally substituted C1-4 alkyl, or optionally substituted C1-4 alkoxy;
each of R3 and R4 is independently H, OH, —CN, halogen, optionally substituted C1-4 alkyl, or optionally substituted C1-4 alkoxy;
R5 is H, OH, —CN, C1-3 alkyl optionally substituted with one or more halogen, or C1-3 alkoxy optionally substituted with one or more halogen; and
Q1 is optionally substituted phenyl or optionally substituted 5- to 10-membered heteroaryl.

### Claim 3 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R5 is H, OH, methyl optionally substituted with one or more halogen, or methoxy optionally substituted with one or more halogen.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R5 is H or OH.

### Claim 6 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein X1 is CR3 and Y1 is CR4; or wherein X1 is CR3 and Y1 is N; or wherein X1 is N and Y1 is CR4.

### Claim at position 7

7-8. (canceled)

### Claim 9

A compound of Formula Ia-1, Ia-2, Ib-1, Ib-2, Ib-3, or Ic-1:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is Q1, —O-Q1, or —CH2-Q1;
R3 is H, OH, —CN, halogen, optionally substituted C1-4 alkyl, or optionally substituted C1-4 alkoxy; and
Q1 is optionally substituted phenyl or optionally substituted 5- to 10-membered heteroaryl.

### Claim 10 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R3 is H.

### Claim 11 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —O-Q1; and
Q1 is optionally substituted phenyl.

### Claim 12 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —O-Q1; and
Q1 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of —CN, halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, and —C(═O)—(C1-4 alkyl).

### Claim 13 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —O-Q1; and
Q1 is phenyl optionally substituted with up to two substituents each independently selected from the group consisting of —CN, halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, and —C(═O)—(C1-4 alkyl), and wherein each substituent on the phenyl is at one meta- or ortho-position.

### Claim 14 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —O-Q1; and
Q1 is phenyl optionally substituted at one meta-position with —CN, halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, or —C(═O)—(C1-4 alkyl).

### Claim 15 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is Q1 or —CH2-Q1.

### Claim 16 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is optionally substituted phenyl or benzyl, wherein the phenyl moiety of the benzyl is optionally substituted phenyl.

### Claim 17 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl or benzyl, wherein the phenyl or the phenyl moiety of the benzyl is optionally substituted with one or more substituents each independently selected from the group consisting of —CN, halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, and —C(═O)—(C1-4 alkyl).

### Claim 18 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl optionally substituted with up to two substituents each independently selected from the group consisting of —CN, halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, and —C(═O)—(C1-4 alkyl).

### Claim 19

(canceled)

### Claim 20 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is optionally substituted 5- to 10-membered heteroaryl.

### Claim 21 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R1 is pyridinyl, pyrazolyl, indolyl, or indazolyl, each optionally substituted with one or more substituents each independently selected from the group consisting of halogen, C1-4 alkyl optionally substituted with one or more halogen, C1-4 alkoxy optionally substituted with one or more halogen, and —C(═O)—(C1-4 alkyl).

### Claim 22 (depends on 1)

The compound according to claim 1 wherein the compound is selected from the group consisting of:
4-amino-7-(3-methoxyphenoxy)-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one;
6-amino-3-phenoxy-6,8-dihydro[1,2,4]triazolo[4,3-a][1,8]naphthyridin-9(5H)-one;
4-amino-7-[3-(trifluoromethyl)phenoxy]-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one;
7-(3-methoxyphenoxy)-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-4-amine;
7-[3-(trifluoromethyl)phenoxy]-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-4-amine;
4-amino-7-(3-chlorophenyl)-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one;
7-(3-acetylphenyl)-4-amino-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one;
4-amino-7-[3-(trifluoromethyl)phenyl]-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one;
4-amino-7-(2-methoxypyridin-3-yl)-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one; and
4-amino-7-phenoxy-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolin-1(2H)-one,
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 1)

A method for treating a condition or disorder in a mammal wherein the method comprises administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and wherein the condition or disorder is selected from the group consisting of acute neurological and psychiatric disorders; stroke; cerebral ischemia; spinal cord trauma; cognitive impairment; head trauma; perinatal hypoxia; cardiac arrest; hypoglycemic neuronal damage; dementia; Alzheimer's disease; Huntington's Chorea; amyotrophic lateral sclerosis; ocular damage; retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's disease; muscular spasms and disorders associated with muscular spasticity; epilepsy; convulsions; migraine; urinary incontinence; substance tolerance; substance withdrawal; psychosis; schizophrenia; negative symptoms associated with schizophrenia; autism; bipolar disorder; depression; cognitive impairment associated with depression; cognitive impairment associated with cancer therapy; anxiety; mood disorders; inflammatory disorders; sepsis; cirrhosis; cancer and/or tumors associated with immune response escape; trigeminal neuralgia; hearing loss; tinnitus; macular degeneration of the eye; emesis; brain edema; pain; tardive dyskinesia; sleep disorders; attention deficit/hyperactivity disorder; attention deficit disorder; disorders that comprise as a symptom a deficiency in attention and/or cognition; and conduct disorder.

### Claim 25

(canceled)
